{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:32:38Z","timestamp":1793046758446,"version":"4.5.0"},"reference-count":212,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jaip.2017.11.023","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T03:16:57Z","timestamp":1515122217000},"page":"38-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"title":["SJS\/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation"],"prefix":"10.1016","volume":"6","author":[{"given":"Katie D.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riichiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ardern-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Beachkofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Carleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chodosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Cibotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Denny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni P.","family":"Dodiuk-Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth N.","family":"Ergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"IV","given":"James H.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuen-Iu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rannakoe J.","family":"Lehloenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7036-1309","authenticated-orcid":false,"given":"Simon","family":"Mallal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri A.","family":"Manolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Mockenhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Ostrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pavlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7534-7266","authenticated-orcid":false,"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8601-8292","authenticated-orcid":false,"given":"Alec","family":"Redwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Roujeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo P.","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajirah N.","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery P.","family":"Struewing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Sueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Trubiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Worley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Shear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2017.11.023_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaci.2015.05.050","article-title":"Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response","volume":"136","author":"White","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.11.023_bib3","unstructured":"Manolio TA, Hutter CM, Avigan M, Cibotti R, Davis RL, Denny JC, et al. Research Directions in Genetically-Mediated Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis. Available from: https:\/\/www.genome.gov\/27560487\/research-directions-in-geneticallymediated-stevensjohnson-syndrometoxic-epidermal-necrolysis\/. Accessed December 7, 2017."},{"key":"10.1016\/j.jaip.2017.11.023_bib4","doi-asserted-by":"crossref","unstructured":"Manolio TA, Hutter CM, Avigan M, Cibotti R, Davis RL, Denny JC, et\u00a0al. Research directions in genetic predispositions to Stevens-Johnson syndrome\/toxic epidermal necrolysis [published online ahead of print November 6, 2017]. Clin Pharmacol Therapeut. https:\/\/doi.org\/10.1002\/cpt.890.","DOI":"10.1002\/cpt.890"},{"key":"10.1016\/j.jaip.2017.11.023_bib5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamadermatol.2017.0160","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines: results of a National Institutes of Health Working Group","volume":"153","author":"Maverakis","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib6","unstructured":"Ergen EN, Holmes JH, Ye F, Luo L, Phillips EJ. Foundations of a North American SJS\/TEN Research Network: results of a web-based survey of dermatologists and surgeons. Presented at: American Burn Association (ABA) 49th Annual Meeting; March 20-24, 2017; Boston, MA."},{"key":"10.1016\/j.jaip.2017.11.023_bib7","unstructured":"Department of Health and Human Services. Serious Adverse Drug Reaction Research (R21). Available from: https:\/\/grants.nih.gov\/grants\/guide\/pa-files\/PAR-16-274.html. Accessed December 7, 2017."},{"key":"10.1016\/j.jaip.2017.11.023_bib8","unstructured":"Department of Health and Human Services. Serious Adverse Drug Reaction Research (R01). Available from: https:\/\/grants.nih.gov\/grants\/guide\/pa-files\/PAR-16-275.html. Accessed December 7, 2017."},{"key":"10.1016\/j.jaip.2017.11.023_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/clpt.2013.55","article-title":"HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children","volume":"94","author":"Amstutz","year":"2013","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2017.11.023_bib10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/epi.12564","article-title":"Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions","volume":"55","author":"Amstutz","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaip.2017.11.023_bib11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/clpt.2011.79","article-title":"Phenotype standardization for immune-mediated drug-induced skin injury","volume":"89","author":"Pirmohamed","year":"2011","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2017.11.023_bib12","first-page":"1152","article-title":"Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population","volume":"72","author":"Carr","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jaip.2017.11.023_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archderm.1991.01680050083008","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany","volume":"127","author":"Schopf","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib15","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jaip.2017.11.023_bib17","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","article-title":"Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"15","author":"Fagot","year":"2001","journal-title":"Aids"},{"key":"10.1016\/j.jaip.2017.11.023_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and\u00a0toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2133.2012.11074.x","article-title":"The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies","volume":"167","author":"Lee","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A\u00a0marker for Stevens-Johnson syndrome\u2026: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2017.11.023_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A\u00a0European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2017.11.023_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2017.11.023_bib25","unstructured":"World Health Organization (WHO) Collaborating Centre for Drug Statistic Methodology, Norwegian Institute of Public Health. ATC\/DDD Index. Available from: http:\/\/www.whocc.no\/atcddd. Accessed December 7, 2017."},{"key":"10.1016\/j.jaip.2017.11.023_bib26","first-page":"111","article-title":"Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation","volume":"32","author":"Sukasem","year":"2014","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.jaip.2017.11.023_bib27","first-page":"478","article-title":"HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity","volume":"5","author":"Puangpetch","year":"2014","journal-title":"Front Genet"},{"key":"10.1016\/j.jaip.2017.11.023_bib28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fphar.2016.00186","article-title":"HLA-B (*) 58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand","volume":"7","author":"Sukasem","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2017.11.023_bib29","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaip.2017.11.023_bib30","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2017.11.023_bib31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cpt.537","article-title":"The Japanese Postmarketing Adverse Event Relief System: a confluence of regulatory science, the legal system, and clinical pharmacology","volume":"102","author":"Tominaga","year":"2017","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2017.11.023_bib32","first-page":"2467","volume":"121","author":"Kitami","year":"2011","journal-title":"Jpn J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib33","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","article-title":"HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"51","author":"Kaniwa","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaip.2017.11.023_bib34","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaip.2017.11.023_bib35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.12788\/j.sder.0057","article-title":"Epidemiology of severe drug hypersensitivity","volume":"33","author":"Dodiuk-Gad","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaip.2017.11.023_bib36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an update","volume":"16","author":"Dodiuk-Gad","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib37","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjd.14799","article-title":"Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"175","author":"Dodiuk-Gad","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11588460-000000000-00000","article-title":"Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"34","author":"Butt","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2017.11.023_bib39","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/BF03262001","article-title":"Internet accounts of serious adverse drug reactions: a study of experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"35","author":"Butt","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2017.11.023_bib40","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjd.13375","article-title":"Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms","volume":"172","author":"Lew","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jaip.2017.11.023_bib42","first-page":"839","article-title":"The 12-Item General Health Questionnaire (GHQ-12): reliability, external validity and factor structure in the Spanish population","volume":"20","author":"Sanchez-Lopez Mdel","year":"2008","journal-title":"Psicothema"},{"key":"10.1016\/j.jaip.2017.11.023_bib43","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.brat.2003.07.010","article-title":"Psychometric properties of the Impact of Event Scale - Revised","volume":"41","author":"Creamer","year":"2003","journal-title":"Behav Res Ther"},{"key":"10.1016\/j.jaip.2017.11.023_bib44","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib45","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/jid.2011.138","article-title":"Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life","volume":"131","author":"Prinsen","year":"2011","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib46","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib47","series-title":"Clinical re-classification of severe skin reactions and evaluation of their etiology in a population-based registry","first-page":"S107","author":"Schroder","year":"1999"},{"key":"10.1016\/j.jaip.2017.11.023_bib48","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/INF.0000000000001476","article-title":"Epidemiology and molecular characteristics of Mycoplasma pneumoniae during an outbreak of M.\u00a0pneumoniae-associated Stevens-Johnson syndrome","volume":"36","author":"Watkins","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaip.2017.11.023_bib49","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1542\/peds.2015-0278","article-title":"Outbreak of Mycoplasma pneumoniae-associated Stevens-Johnson syndrome","volume":"136","author":"Olson","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2017.11.023_bib50","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1093\/jpids\/piw085","article-title":"Characterization of children with recurrent episodes of Stevens Johnson syndrome","volume":"6","author":"Olson","year":"2017","journal-title":"J\u00a0Pediatr Infect Dis Soc"},{"key":"10.1016\/j.jaip.2017.11.023_bib51","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1542\/peds.2010-3322","article-title":"Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children","volume":"128","author":"Finkelstein","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2017.11.023_bib52","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1542\/peds.2008-1923","article-title":"Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis","volume":"123","author":"Levi","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2017.11.023_bib53","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jaad.2016.12.024","article-title":"Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States","volume":"76","author":"Hsu","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/BCR.0000000000000204","article-title":"Pediatric toxic epidermal necrolysis: using SCORTEN and predictive models to predict morbidity when a focus on mortality is not enough","volume":"36","author":"Beck","year":"2015","journal-title":"J\u00a0Burn Care Res"},{"key":"10.1016\/j.jaip.2017.11.023_bib55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2016.03.020","article-title":"Ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in children","volume":"166","author":"Catt","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaip.2017.11.023_bib56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/pde.12158","article-title":"Epidemiology of ophthalmologic disease associated with erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis in hospitalized children in the United States","volume":"31","author":"Moreau","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.1990.01670250049006","article-title":"The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients","volume":"126","author":"Chan","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib58","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib59","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/BCR.0b013e3181eed441","article-title":"Toxic epidermal necrolysis in pregnancy: case report and review of the literature","volume":"31","author":"Struck","year":"2010","journal-title":"J\u00a0Burn Care Res"},{"key":"10.1016\/j.jaip.2017.11.023_bib60","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/cid\/cit021","article-title":"Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population","volume":"56","author":"Carr","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2017.11.023_bib61","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2017.11.023_bib62","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2017.11.023_bib63","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib64","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2017.11.023_bib65","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa0911486","article-title":"Maternal or infant antiretroviral drugs to reduce HIV-1 transmission","volume":"362","author":"Chasela","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib66","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1468-1293.2006.00386.x","article-title":"Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women","volume":"7","author":"Marazzi","year":"2006","journal-title":"HIV Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib67","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7196\/SAMJ.6077","article-title":"Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007-2012","volume":"103","author":"Dube","year":"2013","journal-title":"South African Med J"},{"key":"10.1016\/j.jaip.2017.11.023_bib68","doi-asserted-by":"crossref","first-page":"e0135501","DOI":"10.1371\/journal.pone.0135501","article-title":"Stevens Johnson syndrome and toxic epidermal necrolysis: maternal and foetal outcomes in twenty-two consecutive pregnant HIV infected women","volume":"10","author":"Knight","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jaip.2017.11.023_bib69","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/pds.4067","article-title":"Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis","volume":"25","author":"Stewart","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaip.2017.11.023_bib70","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Guegan","year":"2006","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib71","author":"Pattinson"},{"key":"10.1016\/j.jaip.2017.11.023_bib72","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jaad.2005.09.021","article-title":"Toxic epidermal necrolysis in a mother and fetus","volume":"55","author":"Rodriguez","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib73","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/adc.39.207.517","article-title":"Intrapartum toxic epidermal necrolysis","volume":"39","author":"Sweetnam","year":"1964","journal-title":"Arch Dis Childhood"},{"key":"10.1016\/j.jaip.2017.11.023_bib74","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijgo.2013.12.006","article-title":"Assessment of \u201cfresh\u201d versus \u201cmacerated\u201d as accurate markers of time since intrauterine fetal demise in low-income countries","volume":"125","author":"Gold","year":"2014","journal-title":"Int J Gynaecol Obstetr"},{"key":"10.1016\/j.jaip.2017.11.023_bib75","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bjd.15360","article-title":"Long term complications of Stevens-Johnson syndrome\/toxic epidermal necrolysis: the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multi-disciplinary follow up","volume":"177","author":"Lee","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib76","doi-asserted-by":"crossref","unstructured":"Olteanu C, Shear NH, Chew HF, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, et\u00a0al. Severe physical complications among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis [published online ahead of print October 19, 2017]. Drug Saf. https:\/\/doi.org\/10.1007\/s40264-017-0608-0.","DOI":"10.1007\/s40264-017-0608-0"},{"key":"10.1016\/j.jaip.2017.11.023_bib77","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.bjps.2016.01.034","article-title":"UK guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"69","author":"Creamer","year":"2016","journal-title":"J\u00a0Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.jaip.2017.11.023_bib78","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bjps.2016.04.018","article-title":"UK guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016 (print summary - Full guidelines available at https:\/\/doi.org\/10.1016\/j.bjps.2016.01.034)","volume":"69","author":"Creamer","year":"2016","journal-title":"J\u00a0Plast Reconstruct Aesthet Surg"},{"key":"10.1016\/j.jaip.2017.11.023_bib79","first-page":"S30","article-title":"Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement","volume":"101","author":"Goldman","year":"2017","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2017.11.023_bib80","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaip.2017.11.023_bib81","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaad.2015.08.008","article-title":"Treatment of toxic epidermal necrolysis in North America","volume":"73","author":"Dodiuk-Gad","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000051702","article-title":"Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience","volume":"203","author":"Stella","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaip.2017.11.023_bib83","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/1346-8138.12925","article-title":"Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"42","author":"Aihara","year":"2015","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib84","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/bjd.12607","article-title":"The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre","volume":"169","author":"Lee","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib85","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jaad.2011.12.014","article-title":"Toxic epidermal necrolysis: five years of treatment experience from a burn unit","volume":"67","author":"Firoz","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib86","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.burns.2006.08.014","article-title":"Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis","volume":"33","author":"Stella","year":"2007","journal-title":"Burns"},{"key":"10.1016\/j.jaip.2017.11.023_bib87","first-page":"119","article-title":"Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome","volume":"11","author":"Gravante","year":"2007","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jaip.2017.11.023_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.2005.tb00704.x","article-title":"High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series","volume":"32","author":"Tan","year":"2005","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib89","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/00015550510038232","article-title":"Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients","volume":"85","author":"Kim","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2017.11.023_bib90","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.jaip.2017.11.023_bib91","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.jaip.2017.11.023_bib92","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-4632.2004.02048.x","article-title":"Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis","volume":"43","author":"Al-Mutairi","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib93","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib94","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib95","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2017.11.023_bib96","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib97","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaad.2013.04.007","article-title":"Methylprednisolone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers","volume":"69","author":"Hirahara","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib98","first-page":"743","article-title":"High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases","volume":"20","author":"Chen","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib99","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-4632.2009.04166.x","article-title":"Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China","volume":"48","author":"Yang","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2017.11.023_bib101","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/01.PRS.0000019761.69444.10","article-title":"Outcome of patients with toxic epidermal necrolysis syndrome revisited","volume":"110","author":"Ducic","year":"2002","journal-title":"Plast Reconstruct Surg"},{"key":"10.1016\/j.jaip.2017.11.023_bib102","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/108854100778250914","article-title":"Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases","volume":"21","author":"Tripathi","year":"2000","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2017.11.023_bib103","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A\u00a010-year experience with toxic epidermal necrolysis","volume":"21","author":"Schulz","year":"2000","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.jaip.2017.11.023_bib104","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004630-199709000-00008","article-title":"Toxic epidermal necrolysis","volume":"18","author":"Murphy","year":"1997","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.jaip.2017.11.023_bib105","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib106","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","volume":"71","author":"Kirchhof","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib107","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4103\/0378-6323.116738","article-title":"Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid","volume":"79","author":"Singh","year":"2013","journal-title":"Ind J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaip.2017.11.023_bib108","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib109","first-page":"473","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J\u00a0Trauma"},{"key":"10.1016\/j.jaip.2017.11.023_bib110","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.jid.2017.05.022","article-title":"Ciclosporin use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches","volume":"137","author":"Gonzalez-Herrada","year":"2017","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib111","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jid.2017.07.828","article-title":"New evidence supporting cyclosporine efficacy in epidermal necrolysis","volume":"137","author":"Roujeau","year":"2017","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib112","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib113","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.11.023_bib114","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2133.2009.09585.x","article-title":"Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol [corrected]","volume":"162","author":"de Sica-Chapman","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib115","first-page":"S32","article-title":"Efficacy of tumor necrosis factor\u2014\u03b1 antagonists in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a randomized controlled trial and immunosuppressive effects evaluation","volume":"6","author":"Wang","year":"2016","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2017.11.023_bib116","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2017.11.023_bib117","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ajo.2010.04.026","article-title":"Ophthalmic manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN","volume":"150","author":"Morales","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaip.2017.11.023_bib118","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1398-9995.2006.01295.x","article-title":"Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series","volume":"62","author":"Yip","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.11.023_bib119","first-page":"157","article-title":"Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"145","author":"Gueudry","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib120","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jtos.2016.02.001","article-title":"Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome\/toxic epidermal necrolysis\u2014a comprehensive review and guide to therapy, II: ophthalmic disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jaip.2017.11.023_bib121","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","article-title":"Analysis of\u00a0the acute ophthalmic manifestations of the erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysis disease spectrum","volume":"102","author":"Power","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaip.2017.11.023_bib122","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/ICO.0b013e31802eb264","article-title":"Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management","volume":"26","author":"Chang","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.jaip.2017.11.023_bib123","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ophtha.2010.06.035","article-title":"Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis","volume":"118","author":"Lopez-Garcia","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaip.2017.11.023_bib124","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1038\/srep05981","article-title":"Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications","volume":"4","author":"Ueta","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2017.11.023_bib125","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1038\/srep04862","article-title":"Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement","volume":"4","author":"Ueta","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2017.11.023_bib126","first-page":"581","article-title":"HLA-class I gene polymorphisms in Japanese Stevens-Johnson syndrome patients with ocular surface complications","volume":"116","author":"Nakaji","year":"2012","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.jaip.2017.11.023_bib127","first-page":"550","article-title":"HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese","volume":"14","author":"Ueta","year":"2008","journal-title":"Mol Vision"},{"key":"10.1016\/j.jaip.2017.11.023_bib128","doi-asserted-by":"crossref","first-page":"e43650","DOI":"10.1371\/journal.pone.0043650","article-title":"HLA-A*0206 with TLR3 polymorphisms exerts more than additive effects in Stevens-Johnson syndrome with severe ocular surface complications","volume":"7","author":"Ueta","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.jaip.2017.11.023_bib129","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.ophtha.2011.01.046","article-title":"Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases","volume":"118","author":"Gregory","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaip.2017.11.023_bib130","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/ICO.0b013e31823d02a8","article-title":"Indications and outcomes of amniotic membrane transplantation in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study","volume":"31","author":"Hsu","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jaip.2017.11.023_bib131","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2147\/OPTH.S45054","article-title":"Prompt versus delayed amniotic membrane application in a patient with acute Stevens-Johnson syndrome","volume":"7","author":"Ciralsky","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jaip.2017.11.023_bib132","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ophtha.2016.04.041","article-title":"New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome","volume":"123","author":"Gregory","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaip.2017.11.023_bib133","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/jop.2012.0009","article-title":"Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye","volume":"29","author":"Prabhasawat","year":"2013","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2017.11.023_bib134","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0029-7844(97)00596-6","article-title":"Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases","volume":"91","author":"Meneux","year":"1998","journal-title":"Obstetr Gynecol"},{"key":"10.1016\/j.jaip.2017.11.023_bib135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.bcr.0000194268.01514.f8","article-title":"Long-term follow-up of patients treated for toxic epidermal necrolysis","volume":"27","author":"Oplatek","year":"2006","journal-title":"J\u00a0Burn Care Res"},{"key":"10.1016\/j.jaip.2017.11.023_bib136","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.burns.2015.03.012","article-title":"Complications of Stevens-Johnson syndrome beyond the eye and skin","volume":"42","author":"Saeed","year":"2016","journal-title":"Burns"},{"key":"10.1016\/j.jaip.2017.11.023_bib137","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1468-3083.2006.01586.x","article-title":"Vaginal adenosis induced by Stevens-Johnson syndrome","volume":"20","author":"Emberger","year":"2006","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2017.11.023_bib138","first-page":"81","article-title":"Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"4","author":"Kaser","year":"2011","journal-title":"Rev Obstetr Gynecol"},{"key":"10.1016\/j.jaip.2017.11.023_bib139","doi-asserted-by":"crossref","first-page":"490.e1","DOI":"10.1016\/j.jpurol.2017.01.018","article-title":"Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"13","author":"Van Batavia","year":"2017","journal-title":"J\u00a0Pediatr Urol"},{"key":"10.1016\/j.jaip.2017.11.023_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-060309-164311","article-title":"Role of postmarketing surveillance in contemporary medicine","volume":"62","author":"Woodcock","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib141","unstructured":"US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). Available from: https:\/\/www.fda.gov\/drugs\/informationondrugs\/ucm135151.htm. Accessed December 7, 2017."},{"key":"10.1016\/j.jaip.2017.11.023_bib142","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cpt.320","article-title":"The FDA's Sentinel initiative\u2013a comprehensive approach to medical product surveillance","volume":"99","author":"Ball","year":"2016","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2017.11.023_bib143","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nbt.2749","article-title":"Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data","volume":"31","author":"Denny","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaip.2017.11.023_bib144","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fgene.2014.00184","article-title":"eMERGEing progress in genomics\u2014the first seven years","volume":"5","author":"Crawford","year":"2014","journal-title":"Front Genet"},{"key":"10.1016\/j.jaip.2017.11.023_bib145","doi-asserted-by":"crossref","first-page":"e1002823","DOI":"10.1371\/journal.pcbi.1002823","article-title":"Chapter 13: mining electronic health records in the genomics era","volume":"8","author":"Denny","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.jaip.2017.11.023_bib146","doi-asserted-by":"crossref","first-page":"79re1","DOI":"10.1126\/scitranslmed.3001807","article-title":"Electronic medical records for genetic research: results of the eMERGE consortium","volume":"3","author":"Kho","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib147","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13073-015-0166-y","article-title":"Extracting research-quality phenotypes from electronic health records to support precision medicine","volume":"7","author":"Wei","year":"2015","journal-title":"Genome Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib148","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jamia\/ocv202","article-title":"PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability","volume":"23","author":"Kirby","year":"2016","journal-title":"J\u00a0Am Med Inform Assoc"},{"key":"10.1016\/j.jaip.2017.11.023_bib149","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ajhg.2011.09.008","article-title":"Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies","volume":"89","author":"Denny","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaip.2017.11.023_bib150","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/tpj.2015.51","article-title":"A\u00a0genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough","volume":"16","author":"Mosley","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2017.11.023_bib151","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1160\/TH14-08-0670","article-title":"A\u00a0genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record","volume":"113","author":"Karnes","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaip.2017.11.023_bib152","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/pds.3778","article-title":"Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases","volume":"24","author":"Davis","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaip.2017.11.023_bib153","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib154","doi-asserted-by":"crossref","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2017.11.023_bib155","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1212\/WNL.0b013e31826aac73","article-title":"Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore","volume":"79","author":"Dong","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jaip.2017.11.023_bib156","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/tpj.2013.46","article-title":"Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study","volume":"14","author":"Toh","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2017.11.023_bib157","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpt.683","article-title":"Pharmacogenomic advances in the prediction and prevention of cutaneous idiosyncratic drug reactions","volume":"102","author":"Pan","year":"2017","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2017.11.023_bib158","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1212\/WNL.0000000000001034","article-title":"Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions","volume":"83","author":"Chen","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jaip.2017.11.023_bib159","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2217\/pgs.15.125","article-title":"Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore","volume":"16","author":"Dong","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2017.11.023_bib160","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2217\/pgs-2017-0016","article-title":"Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach","volume":"18","author":"Tan-Koi","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2017.11.023_bib161","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jid.2016.02.808","article-title":"Impact of the HLA-B(*)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions","volume":"136","author":"Ng","year":"2016","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib162","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2017.11.023_bib163","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2017.11.023_bib164","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2017.11.023_bib165","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2017.11.023_bib166","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice","volume":"5","author":"Peter","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2017.11.023_bib167","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000248097","article-title":"HLA and allopurinol drug eruption","volume":"179","author":"Chan","year":"1989","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaip.2017.11.023_bib168","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1750-1172-6-52","article-title":"Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe","volume":"6","author":"Genin","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2017.11.023_bib169","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.yebeh.2010.08.007","article-title":"Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China","volume":"19","author":"Wu","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.jaip.2017.11.023_bib170","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.seizure.2011.02.003","article-title":"Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland","volume":"20","author":"Wang","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.jaip.2017.11.023_bib171","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00228-011-1009-4","article-title":"Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients","volume":"67","author":"Zhang","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2017.11.023_bib172","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000003453","article-title":"Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jaip.2017.11.023_bib173","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2017.11.023_bib174","first-page":"29","article-title":"The HLA-A*31:01 allele: influence on carbamazepine treatment","volume":"10","author":"Yip","year":"2017","journal-title":"Pharmacogenomics Pers Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib175","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib176","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0029-1240009","article-title":"Genetic association studies in drug-induced liver injury","volume":"29","author":"Daly","year":"2009","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jaip.2017.11.023_bib177","unstructured":"The Allele Frequency Net Database. Allele, haplotype and genotype frequencies in world populations. Available from: allelefrequencies.net. Accessed December 7, 2017."},{"key":"10.1016\/j.jaip.2017.11.023_bib178","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2017.11.023_bib179","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FPC.0000000000000211","article-title":"Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population","volume":"26","author":"Tassaneeyakul","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2017.11.023_bib180","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib181","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/jid.2015.165","article-title":"Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions","volume":"135","author":"Chung","year":"2015","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib182","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2007.06.017","article-title":"HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome","volume":"120","author":"Yang","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.11.023_bib183","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome","volume":"129","author":"Wei","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.11.023_bib184","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2017.11.023_bib185","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2017.11.023_bib186","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib187","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1345\/aph.1K001","article-title":"Etanercept for toxic epidermal necrolysis","volume":"41","author":"Famularo","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaip.2017.11.023_bib188","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1346-8138.2009.00616.x","article-title":"Toxic epidermal necrolysis successfully treated with etanercept","volume":"36","author":"Gubinelli","year":"2009","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib189","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/ajt.12698","article-title":"First-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejection","volume":"14","author":"Flechner","year":"2014","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jaip.2017.11.023_bib190","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaci.2013.04.036","article-title":"A\u00a0new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders","volume":"132","author":"Wang","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.11.023_bib191","doi-asserted-by":"crossref","first-page":"245ra95","DOI":"10.1126\/scitranslmed.3008227","article-title":"An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions","volume":"6","author":"Saito","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib192","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nrc3153","article-title":"Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaip.2017.11.023_bib193","unstructured":"MediPaper Medical Communications Ltd. List of U.S. FDA Approved ImmuneCheckpoint Inhibitors. Available from: https:\/\/medi-paper.com\/approved-immunotherapies\/. Accessed December 7, 2017."},{"key":"10.1016\/j.jaip.2017.11.023_bib194","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaip.2017.11.023_bib195","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib196","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1056\/NEJMc1114329","article-title":"Vemurafenib sensitivity skin reaction after ipilimumab","volume":"366","author":"Harding","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib197","first-page":"149","article-title":"Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma","volume":"39","author":"Nayar","year":"2016","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jaip.2017.11.023_bib198","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.jaip.2017.11.023_bib199","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib200","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaip.2017.11.023_bib201","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaip.2017.11.023_bib202","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1172\/JCI72932","article-title":"Memory regulatory T cells reside in human skin","volume":"124","author":"Sanchez Rodriguez","year":"2014","journal-title":"J\u00a0Clin Investigat"},{"key":"10.1016\/j.jaip.2017.11.023_bib203","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.immuni.2015.10.016","article-title":"A\u00a0wave of regulatory T cells into neonatal skin mediates tolerance to commensal microbes","volume":"43","author":"Scharschmidt","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2017.11.023_bib204","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature10664","article-title":"Response to self antigen imprints regulatory memory in tissues","volume":"480","author":"Rosenblum","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2017.11.023_bib205","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1346-8138.2012.01532.x","article-title":"Distinguishing between erythema multiforme major and Stevens-Johnson syndrome\/toxic epidermal necrolysis immunopathologically","volume":"39","author":"Iwai","year":"2012","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib206","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","article-title":"Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome","volume":"182","author":"Takahashi","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2017.11.023_bib207","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/eji.200425773","article-title":"Prevention of toxic epidermal necrolysis by regulatory T cells","volume":"35","author":"Azukizawa","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaip.2017.11.023_bib208","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4049\/jimmunol.1602029","article-title":"The effect of inhibitory signals on the priming of drug hapten-specific T cells that express distinct Vbeta receptors","volume":"199","author":"Gibson","year":"2017","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2017.11.023_bib209","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib210","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2017.11.023_bib211","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2017.11.023_bib212","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321981730911X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321981730911X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:13:30Z","timestamp":1761974010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221321981730911X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":212,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S221321981730911X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2017.11.023","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SJS\/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2017.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}